drugset / Trial / NCT01074502

Apremilast in the Treatment of Moderate to Severe Acne

NCT01074502

NaSingle-groupOpen-labelTreatment

Summary

Acne is a chronic inflammatory disease of the pilosebaceous unit that affects 80-90% of the population, especially teenagers, although adult acne is a significant problem for 3-6 % of adult men and 5-12% of adult women. Although acne is not a life-threatening disease, it produces significant psychological disturbances and permanent skin scars. A novel anti-inflammatory, not antibiotic drug may be an excellent alternative for the treatment of moderate to severe acne. Apremilast has been shown to inhibit the production of tumor necrosis factor (TNF)-alpha, IL-8 and neutrophil infiltration, all of which are elevated in inflammatory acne. Our intention is to study Apremilast in the treatment of moderate to severe acne.

Timeline

Start
2010-02
Primary completion
2010-07
Completion
2010-10

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 20 mg Oral

Indications